Vanessa Sciacca, Christian Sohns, Harry J.G.M. Crijns, Nassir F. Marrouche, Rene Schramm, Maximilian Moersdorf, Thomas Fink, Leonard Bergau, Gerhard Hindricks, Nikolaos Dagres, Samuel Sossalla, Angelika Costard-Jaeckle, Henrik Fox, Mustapha El Hamriti, Frank Konietschke, Volker Rudolph, Jan Gummert, Jan G.P. Tijssen, Philipp Sommer
The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF). Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF.
{"title":"Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end-stage heart failure: Lessons from CASTLE-HTx","authors":"Vanessa Sciacca, Christian Sohns, Harry J.G.M. Crijns, Nassir F. Marrouche, Rene Schramm, Maximilian Moersdorf, Thomas Fink, Leonard Bergau, Gerhard Hindricks, Nikolaos Dagres, Samuel Sossalla, Angelika Costard-Jaeckle, Henrik Fox, Mustapha El Hamriti, Frank Konietschke, Volker Rudolph, Jan Gummert, Jan G.P. Tijssen, Philipp Sommer","doi":"10.1002/ejhf.3505","DOIUrl":"https://doi.org/10.1002/ejhf.3505","url":null,"abstract":"The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF). Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"25 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter regarding the article ‘Predictors of the efficacy of His bundle pacing in patients with a prolonged PR interval: A stratified analysis of the HOPE-HF randomized controlled trial’","authors":"Anja Zupan Mežnar, Miha Mrak, David Žižek","doi":"10.1002/ejhf.3490","DOIUrl":"https://doi.org/10.1002/ejhf.3490","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"110 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicolas Girerd, Adriaan A. Voors, Jozine Ter Maaten
Click on the article title to read more.
点击文章标题阅读更多内容。
{"title":"Exploring the role of hypertonic saline in ambulatory heart failure management: One size does not fit all?","authors":"Nicolas Girerd, Adriaan A. Voors, Jozine Ter Maaten","doi":"10.1002/ejhf.3500","DOIUrl":"https://doi.org/10.1002/ejhf.3500","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"35 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jonas Sundermeyer, Caroline Kellner, Benedikt N. Beer, Angela Dettling, Lisa Besch, Stefan Blankenberg, Ingo Eitel, Derk Frank, Norbert Frey, Tobias Graf, Paulus Kirchhof, Jannis Krais, Dirk von Lewinski, Norman Mangner, Sven Möbius-Winkler, Peter Nordbeck, Martin Orban, Matthias Pauschinger, Can Martin Sag, Clemens Scherer, Carsten Skurk, Holger Thiele, Dirk Westermann, Benedikt Schrage
The optimal timing for implementing mechanical circulatory support (MCS) in cardiogenic shock (CS) remains indeterminate. This study aims to evaluate patient characteristics and outcome associated with the time interval between CS onset and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) implementation.
{"title":"Timing of veno-arterial extracorporeal membrane oxygenation support in patients with cardiogenic shock","authors":"Jonas Sundermeyer, Caroline Kellner, Benedikt N. Beer, Angela Dettling, Lisa Besch, Stefan Blankenberg, Ingo Eitel, Derk Frank, Norbert Frey, Tobias Graf, Paulus Kirchhof, Jannis Krais, Dirk von Lewinski, Norman Mangner, Sven Möbius-Winkler, Peter Nordbeck, Martin Orban, Matthias Pauschinger, Can Martin Sag, Clemens Scherer, Carsten Skurk, Holger Thiele, Dirk Westermann, Benedikt Schrage","doi":"10.1002/ejhf.3498","DOIUrl":"https://doi.org/10.1002/ejhf.3498","url":null,"abstract":"The optimal timing for implementing mechanical circulatory support (MCS) in cardiogenic shock (CS) remains indeterminate. This study aims to evaluate patient characteristics and outcome associated with the time interval between CS onset and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) implementation.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"64 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan Manuel Salvador-Casabón, Isaac Lacambra-Blasco, Juan Ignacio Pérez-Calvo
Click on the article title to read more.
点击文章标题阅读更多内容。
{"title":"Letter regarding the article ‘Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry’","authors":"Juan Manuel Salvador-Casabón, Isaac Lacambra-Blasco, Juan Ignacio Pérez-Calvo","doi":"10.1002/ejhf.3493","DOIUrl":"https://doi.org/10.1002/ejhf.3493","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"14 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is it possible to establish a threshold to define the inflammatory risk of acute heart failure patients? Letter regarding the article ‘Burst steroid therapy for acute heart failure: the CORTAHF randomized, open-label, pilot trial’","authors":"Massimiliano Camilli","doi":"10.1002/ejhf.3494","DOIUrl":"https://doi.org/10.1002/ejhf.3494","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"63 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Le Li, Ligang Ding, Lingmin Wu, Zhicheng Hu, Limin Liu, Minghao Zhao, Tao Zhang, Lihui Zheng, Yan Yao
To estimate the global burden of myocarditis in the general population from 1990 to 2021.
估算 1990 年至 2021 年全球普通人群中心肌炎的发病率。
{"title":"The global, regional, and national burden of myocarditis in 204 countries and territories, 1990–2021: Results from the Global Burden of Disease Study 2021","authors":"Le Li, Ligang Ding, Lingmin Wu, Zhicheng Hu, Limin Liu, Minghao Zhao, Tao Zhang, Lihui Zheng, Yan Yao","doi":"10.1002/ejhf.3483","DOIUrl":"https://doi.org/10.1002/ejhf.3483","url":null,"abstract":"To estimate the global burden of myocarditis in the general population from 1990 to 2021.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"45 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Baudry and colleagues reported trends in durable mechanical circulatory support (MCS), primarily left ventricular assist devices (LVADs), across Europe from 2018 to 2023.<span><sup>1</sup></span> They highlighted the underutilization of durable MCS, despite heart failure (HF) remaining a leading cause of mortality. Their hypotheses—improvements in medical therapies, referral delays to advanced HF units, the COVID-19 pandemic, and changes in graft allocation—are valid. However, the period from 2018 to 2023 cannot be considered a single therapeutic era, as significant advancements in HF with reduced ejection fraction (HFrEF), including sodium–glucose cotransporter 2 inhibitors and vericiguat (in some countries), were only implemented in 2022.<span><sup>2</sup></span></p> <p>We commend the authors for this unprecedent analysis but would like to offer a more optimistic perspective. Since 2022, durable MCS including LVADs and Aeson® total artificial hearts (TAHs) have been gaining traction in Europe. LVAD implantations increased across most countries between 2022 and 2023, from +2% in Austria to +25% in the Czech Republic and Germany, and + 51% in Poland. Though France initially lagged, it is showing strong momentum in 2024 with 118 LVADs (matching 2023's total) and forecasts of 165 LVADs by the end of the year. Additionally, 45 Aeson® TAH devices have been implanted across Europe since the programme resumed in November 2022, primarily in France, Germany, and Italy. Once again, France leads the way with 20 TAHs already implanted and a projection of 30 by the end of the year.</p> <p>Awareness is growing that death from HF is no longer inevitable and that durable MCS is an accessible, life-saving therapy. First, clinicians recognize that despite optimal medical management, one in five HFrEF patients progresses to advanced HF and may require durable MCS.<span><sup>3</sup></span> Second, improved communication within the cardiology community has increased acceptance of durable MCS. The rise in advanced HF sessions at congresses and a growing body of scientific publications reflect this trend. As expertise grows in implantation, device optimization, and long-term management, physicians are more confident in highlighting the benefits of durable MCS rather than focusing on its drawbacks.</p> <p>More physicians now regard durable MCS as an option for life. The European ELEVATE registry has been instructive, providing real-world data easily translatable to clinical practice showing a 5-year survival rate of 63% with LVAD, alongside significant improvements in functional capacity and quality of life.<span><sup>4</sup></span> In parallel, physicians are gradually recognizing that durable MCS and heart transplant are complementary, not competing. Durable MCS is a valuable bridge to transplant for critically ill INTERMACS 1–2 patients, provides crucial rehabilitation and family time for INTERMACS 3–4 patients at limited access to transplant. It also provides an
{"title":"Letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’","authors":"Anne-Céline Martin","doi":"10.1002/ejhf.3484","DOIUrl":"https://doi.org/10.1002/ejhf.3484","url":null,"abstract":"<p>Baudry and colleagues reported trends in durable mechanical circulatory support (MCS), primarily left ventricular assist devices (LVADs), across Europe from 2018 to 2023.<span><sup>1</sup></span> They highlighted the underutilization of durable MCS, despite heart failure (HF) remaining a leading cause of mortality. Their hypotheses—improvements in medical therapies, referral delays to advanced HF units, the COVID-19 pandemic, and changes in graft allocation—are valid. However, the period from 2018 to 2023 cannot be considered a single therapeutic era, as significant advancements in HF with reduced ejection fraction (HFrEF), including sodium–glucose cotransporter 2 inhibitors and vericiguat (in some countries), were only implemented in 2022.<span><sup>2</sup></span></p>\u0000<p>We commend the authors for this unprecedent analysis but would like to offer a more optimistic perspective. Since 2022, durable MCS including LVADs and Aeson® total artificial hearts (TAHs) have been gaining traction in Europe. LVAD implantations increased across most countries between 2022 and 2023, from +2% in Austria to +25% in the Czech Republic and Germany, and + 51% in Poland. Though France initially lagged, it is showing strong momentum in 2024 with 118 LVADs (matching 2023's total) and forecasts of 165 LVADs by the end of the year. Additionally, 45 Aeson® TAH devices have been implanted across Europe since the programme resumed in November 2022, primarily in France, Germany, and Italy. Once again, France leads the way with 20 TAHs already implanted and a projection of 30 by the end of the year.</p>\u0000<p>Awareness is growing that death from HF is no longer inevitable and that durable MCS is an accessible, life-saving therapy. First, clinicians recognize that despite optimal medical management, one in five HFrEF patients progresses to advanced HF and may require durable MCS.<span><sup>3</sup></span> Second, improved communication within the cardiology community has increased acceptance of durable MCS. The rise in advanced HF sessions at congresses and a growing body of scientific publications reflect this trend. As expertise grows in implantation, device optimization, and long-term management, physicians are more confident in highlighting the benefits of durable MCS rather than focusing on its drawbacks.</p>\u0000<p>More physicians now regard durable MCS as an option for life. The European ELEVATE registry has been instructive, providing real-world data easily translatable to clinical practice showing a 5-year survival rate of 63% with LVAD, alongside significant improvements in functional capacity and quality of life.<span><sup>4</sup></span> In parallel, physicians are gradually recognizing that durable MCS and heart transplant are complementary, not competing. Durable MCS is a valuable bridge to transplant for critically ill INTERMACS 1–2 patients, provides crucial rehabilitation and family time for INTERMACS 3–4 patients at limited access to transplant. It also provides an","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"4 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Henri Lu, Brian L. Claggett, Milton Packer, Marc A. Pfeffer, Karl Swedberg, Jean Rouleau, Michael R. Zile, Martin Lefkowitz, Akshay S. Desai, Pardeep S. Jhund, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Resting heart rate (HR) is a strong risk marker in patients with heart failure (HF), but the clinical implications of visit-to-visit changes in HR (ΔHR) are less well established. We aimed to explore the association between ΔHR and subsequent outcomes in a pooled dataset of two well-characterized cohorts of patients with HF across the full range of left ventricular ejection fraction (LVEF).
{"title":"Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials","authors":"Henri Lu, Brian L. Claggett, Milton Packer, Marc A. Pfeffer, Karl Swedberg, Jean Rouleau, Michael R. Zile, Martin Lefkowitz, Akshay S. Desai, Pardeep S. Jhund, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan","doi":"10.1002/ejhf.3487","DOIUrl":"https://doi.org/10.1002/ejhf.3487","url":null,"abstract":"Resting heart rate (HR) is a strong risk marker in patients with heart failure (HF), but the clinical implications of visit-to-visit changes in HR (ΔHR) are less well established. We aimed to explore the association between ΔHR and subsequent outcomes in a pooled dataset of two well-characterized cohorts of patients with HF across the full range of left ventricular ejection fraction (LVEF).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"35 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gad Cotter, Beth A. Davison, Yonathan Freund, Alexandre Mebazaa
Click on the article title to read more.
点击文章标题阅读更多内容。
{"title":"Reply to ‘Is it possible to establish a threshold to define the inflammatory risk of acute heart failure patients?’ Letter regarding the article ‘Burst steroid therapy for acute heart failure: The CORTAHF randomized, open-label, pilot trial’","authors":"Gad Cotter, Beth A. Davison, Yonathan Freund, Alexandre Mebazaa","doi":"10.1002/ejhf.3491","DOIUrl":"https://doi.org/10.1002/ejhf.3491","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"1 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：